Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

400
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
400
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

404
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
404
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

546
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
546
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunotherapy with or without low-intensity chemotherapy versus conventional chemotherapy as first-line treatment for newly diagnosed B-ALL patients fit for intensive chemotherapy: a propensity score-matched study.

Frontiers in medicine·2026
Same author

Manipulating CD38 ectoenzymatic activity revitalizes regulatory T cells via deacetylase Sirt-1 in immune thrombocytopenia.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Chaperone-mediated autophagy reprograms heterogeneous subsets of activated macrophages in immune thrombocytopenia.

Autophagy·2026
Same author

Efficient Detection of Trace NO<sub>2</sub> in Humid Environments Induced by Increasing Formation of Free Radicals on SV-MoS<sub>2</sub>/Au.

ACS sensors·2026
Same author

Exploring the Burden on Patients Living With and Receiving Treatment for Immune Thrombocytopenia (ITP): Patient and Physician Perceptions From the ITP World Impact Survey (I-WISh) 2.0.

American journal of hematology·2026
Same author

Synopsis of the 2025 guideline for the diagnosis and management of adult primary immune thrombocytopenia.

Chinese medical journal·2026

Related Experiment Video

Updated: Feb 25, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.7K

Novel agents for anti-platelet therapy.

Xuebin Ji1, Ming Hou

  • 1Department of Hematology, QiLu Hospital of Shandong University, Jinan, China PR. houming@medmail.com.cn

Journal of Hematology & Oncology
|November 8, 2011
PubMed
Summary

Anti-platelet drugs are crucial for treating thrombotic diseases and preventing cardiovascular events. Ongoing research focuses on developing new agents with improved efficacy and reduced bleeding risks for better patient outcomes.

Area of Science:

  • Pharmacology
  • Cardiology
  • Hematology

Background:

  • Anti-platelet therapy is vital for managing thrombotic disorders and preventing cardio-cerebrovascular diseases.
  • Established drugs like aspirin, clopidogrel, and glycoprotein IIb/IIIa antagonists are widely used.
  • Emerging drug classes, including P2Y12 inhibitors and protease-activated receptor antagonists, offer new therapeutic avenues.

Purpose of the Study:

  • To review the current landscape of anti-platelet agents.
  • To evaluate the efficacy and safety profiles of existing and novel anti-platelet drugs.
  • To highlight the need for further research into selective platelet inhibitors with improved risk-benefit ratios.

Main Methods:

  • Literature review of anti-platelet therapies.

More Related Videos

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

1.0K
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

23.3K

Related Experiment Videos

Last Updated: Feb 25, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.7K
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

1.0K
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

23.3K
  • Analysis of clinical benefits and adverse events associated with various drug classes.
  • Discussion of ongoing clinical trials and future drug development.

    • Main Results:

    • Aspirin, clopidogrel, and glycoprotein IIb/IIIa antagonists are effective but carry risks of thrombosis and bleeding.
    • Platelet adenosine diphosphate P2Y12 receptor antagonists demonstrate significant protective effects.
    • Newer agents like protease-activated receptor antagonists show potential for reduced bleeding complications.

    Conclusions:

    • The increasing number of anti-platelet drugs necessitates careful evaluation of their real-world efficacy and safety, particularly hemorrhagic risks.
    • Further development of selective platelet inhibitors with high anti-thrombotic efficacy and low bleeding side effects is warranted.
    • Optimizing anti-platelet therapy requires a balance between preventing ischemic events and minimizing bleeding complications.